

APPLICATION NO.
10/051,243

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

APPLICANT
Maurice ISRAËL et al.

FILING DATE
JANUARY 22, 2002




GROUP
UNASSIGNED

FEB 20 2002

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no
	WO 98/51291		PCT	11/19/1998		(English language abstract)
	EP 0 631 777		EUROPE	01/04/1995		
	EP 0 146 338		EUROPE	06/26/1985		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	MATTEI et al., "Naftazone reduces glutamate cerebro spinal fluid levels in rats and glutamate release from mouse cerebellum synaptosomes," <i>Neuroscience Letters</i> , 1999, pp. 183-86, vol. 271, Elsevier Science Ireland Ltd., Ireland.
	AZZA et al., "Lipid Peroxidation and Lysosomal Integrity in Different Inflammatory Models in Rats: The Effects of Indomethacin and Naftazone," <i>Pharmacological Research</i> , 1995, pp. 279-85, The Italian Pharmacological Society, Italy.
	ZICOT, "Etude multicentrique de l'efficacite et de la tolerance de la naftazone (Mediaven® 10 MG). Comparaison de deux schemas posologiques," <i>Revue Medicale De Liege</i> , April, 1993, pp. 224-28, France.
	HERBER et al., "Reduction and Glucuronidation of Naftazone by Human and Rat Liver Microsomes," <i>Drug Metabolism and Disposition</i> , 1995, pp. 1305-14, Vol. 23, No. 12, The American Society for Pharmacology and Experimental Therapeutics, Bethesda, Maryland, USA.
Examiner Signature	Date Considered 9/23/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.